Dietary quality in early-onset gastrointestinal malignancies: NHANES 2005-2018. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback